The current study examined the influence of guilt on young children's honesty about their transgression. Children (N = 192; 4-6 years of age; 49.5% male, 50.5% female; middle-income Chinese families) participated in a modified temptation resistance paradigm where they were asked not to peek at a toy in the absence of an experimenter. Next, the children were randomly assigned to 1 of 3 conditions: (a) guilt condition, where children were induced with guilt using a revised mishap paradigm; (b) sadness condition, where children were induced with sadness by watching a video; and (c) baseline condition, where children did not participate in any additional emotion-inducing task. When later questioned about whether they peeked at the toy, children in the guilt condition were significantly less likely to lie compared with those in the sadness or baseline conditions. There was no significant difference between the sadness and baseline conditions. (PsycInfo Database Record (c) 2022 APA, all rights reserved).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1037/dev0001323 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The eighth annual US DOHAD meeting: promising approaches in epigenetics research of early life exposures.
Epigenomics
January 2025
Department of Anthropology, University of California San Diego, La Jolla, CA, USA.
The U.S. Developmental Origins of Health and Disease (DOHaD) meeting is an annual conference of primarily U.
View Article and Find Full Text PDFPhenotypic Classification of Multisystem Inflammatory Syndrome in Children Using Latent Class Analysis.
JAMA Netw Open
January 2025
Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
Importance: Multisystem inflammatory syndrome in children (MIS-C) is an uncommon but severe hyperinflammatory illness that occurs 2 to 6 weeks after SARS-CoV-2 infection. Presentation overlaps with other conditions, and risk factors for severity differ by patient. Characterizing patterns of MIS-C presentation can guide efforts to reduce misclassification, categorize phenotypes, and identify patients at risk for severe outcomes.
View Article and Find Full Text PDFNew Genetic Variations in RNA-binding Protein Gene and Breast Cancer Risk: A Case-Control Study.
Asian Pac J Cancer Prev
January 2025
Department of Biology, Faculty of Science, University of Sistan and Baluchestan, Zahedan, Iran.
Background: LIN28, a highly conserved RNA-binding protein, regulate a wide variety of post-transcriptional cellular processes. The current study aimed to identify genetic variants of five single nucleotide polymorphisms (SNPs) in the LIN28B gene (rs221634, rs22163, rs314276, rs9404590, and rs12194974) and their association with Breast cancer.
Method: 220 patients and 230 controls were genotyped by the RFLP assay for Lin28B gene variants.
Efficacy and Safety of Proactive Therapy with 2% Crisaborole Ointment in Children with Mild-to-Moderate Atopic Dermatitis: A Randomized Controlled Study.
Paediatr Drugs
January 2025
Department of Dermatology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, China.
Background: The effectiveness of crisaborole for proactive treatment of atopic dermatitis (AD) is not well established.
Objectives: This study aims to investigate the efficacy and safety of a proactive treatment strategy with 2% crisaborole ointment for managing mild-to-moderate AD in children.
Patients And Methods: In this 16-week randomized-controlled trial, children aged 2-17 years with mild-to-moderate AD were enrolled.
Pharmacological Aspects in the Management of Children and Adolescents with Prader-Willi Syndrome.
Paediatr Drugs
January 2025
Division of Endocrinology, Department of Pediatrics, University of Florida, PO Box 100296, Gainesville, FL, 32610, USA.
Prader-Willi syndrome is a rare neurodevelopmental disorder that impacts the musculoskeletal, endocrine, pulmonary, neurologic, ocular, and gastrointestinal systems. In addition, individuals with Prader-Willi syndrome have issues with cognitive development, characteristic behavioral problems, and perhaps most profoundly, appetite control. Currently, the only US Food and Drug Administration-approved therapy for Prader-Willi syndrome is growth hormone, which has been Food and Drug Administration approved for > 20 years for the treatment of growth failure in Prader-Willi syndrome.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!